Release Notes  tranSMART Release Notes

Johnson & Johnson Clinical Trials in tranSMART Search

The following table shows the list of Johnson &  Johnson clinical trials that can be included in a tranSMART search result.

Trial

Title

Platform

C0168T37

A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with Active Ulcerative Colitis.

Affymetrix Human Genome U133 Plus 2.0 array

C0168T44

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Subjects with Plaque-type Psoriasis.

Affymetrix Human Genome U133 Plus 2.0 array

C0168T48

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (REMICADE®) in Subjects with Chronic Sarcoidosis with Pulmonary Involvement.

RBM

C0379T02

A Phase I, Double-blind, Placebo-controlled Study Evaluating the Safety and Pharmacology of Single Subcutaneous Administrations of Human Monoclonal Antibody to IL-12 (CNTO 1275) in Subjects with Moderate to Severe Psoriasis Vulgaris.

DNA

C0379T03

A Phase I, Double-blind, Placebo-controlled Study Evaluating the Safety and Pharmacology of Single Subcutaneous Administrations of Human Monoclonal Antibody to IL-12 (CNTO 1275) in Subjects with Relapsing Forms of Multiple Sclerosis.

DNA

C0379T07

A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn’s Disease.

Affymetrix Human Genome U133 Plus 2.0 array

C0524T03

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety Of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma.

Affymetrix Human Genome U133 Plus 2.0 array

C0743T10

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis.

RBM

C0743T12

A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis.

Affymetrix Human Genome U133 Plus 2.0 array

C0743X01`

Detection of Mediators of Sarcoidosis Skin Lesions.

Affymetrix Human Genome U133 Plus 2.0 array, RBM